Back to GetFilings.com



Table of Contents


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2003

Commission File Number 1-14798


IVAX DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)


 

  Delaware
(State or other jurisdiction of
incorporation or organization)
  11-3500746
(I.R.S. Employer
Identification No.)
 

  2140 North Miami Avenue, Miami, Florida
(Address of principal executive offices)
  33127
(Zip Code)
 

(305) 324-2300
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

27,534,079 shares of Common Stock, $ .01 par value, outstanding as of May 6, 2003.





Table of Contents

IVAX DIAGNOSTICS, INC.

INDEX

 

 

 

 

 

 

PAGE NO.

 

 

 

 

 

 

PART I

 

FINANCIAL INFORMATION

 

 

 

 

 

 

 

 

 

Item 1

 

Financial Statements

 

 

 

 

 

 

 

 

 

 

 

Consolidated Balance Sheets as of March 31, 2003 and December 31, 2002

2

 

 

 

 

 

 

 

 

 

 

Consolidated Statements of Operations for the three months ended March 31, 2003 and 2002

3

 

 

 

 

 

 

 

 

 

 

Consolidated Statements of Cash Flows for the three months ended March 31, 2003 and 2002

4

 

 

 

 

 

 

 

 

 

 

Notes to Consolidated Financial Statements

5

 

 

 

 

 

 

 

 

Item 2

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

11

 

 

 

 

 

 

 

 

Item 3

 

Quantitative and Qualitative Disclosures about Market Risk

19

 

 

 

 

 

 

 

 

Item 4

 

Controls and Procedures

20

 

 

 

 

 

 

PART II

 

OTHER INFORMATION

 

 

 

 

 

 

 

 

 

Item 1

 

Legal Proceedings

21

 

 

 

 

 

 

 

 

Item 6

 

Exhibits and Reports on Form 8-K

22





Table of Contents

PART I - FINANCIAL INFORMATION

Item 1 - Financial Statements

IVAX DIAGNOSTICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

 

 

 

March 31,
2003

 

December 31,
2002

 

 

 


 


 

 

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

16,389,167

 

$

15,941,663

 

Accounts receivable, net of allowances for doubtful accounts of $2,553,516 in 2003 and $2,392,553 in 2002

 

 

6,354,435

 

 

5,721,400

 

Inventories

 

 

3,999,962

 

 

4,246,893

 

Other current assets

 

 

1,356,972

 

 

1,267,827

 

 

 



 



 

Total current assets

 

 

28,100,536

 

 

27,177,783

 

Property, plant and equipment, net

 

 

1,959,971

 

 

1,995,997

 

Goodwill, net

 

 

6,771,883

 

 

6,794,147

 

Equipment on lease

 

 

1,156,870

 

 

1,189,456

 

Other assets

 

 

272,769

 

 

265,321

 

 

 



 



 

Total assets

 

$

38,262,029

 

$

37,422,704

 

 

 



 



 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

829,815

 

$

881,657

 

Accrued expenses and other current liabilities

 

 

3,543,740

 

 

2,775,110

 

 

 



 



 

Total current liabilities

 

 

4,373,555

 

 

3,656,767

 

 

 



 



 

Other long-term liabilities

 

 

402,004

 

 

370,405

 

 

 



 



 

Commitments and contingencies

 

 

 

 

 

 

 

Shareholders’ equity:

 

 

 

 

 

 

 

Common stock, $0.01 par value, authorized 50,000,000 shares,issued and outstanding 27,519,079 in 2003 and 2002

 

 

275,190

 

 

275,190

 

Capital in excess of par value

 

 

43,244,204

 

 

43,095,554

 

Accumulated deficit

 

 

(8,713,769

)

 

(8,426,409

)

Accumulated other comprehensive loss

 

 

(1,319,155

)

 

(1,548,803

)

 

 



 



 

Total shareholders’ equity

 

 

33,486,470

 

 

33,395,532

 

 

 



 



 

Total liabilities and shareholders’ equity

 

$

38,262,029

 

$

37,422,704

 

 

 



 



 


The accompanying Notes to Consolidated Financial Statements are an integral part of these balance sheets.


2


Table of Contents

IVAX DIAGNOSTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

 

Three Months Ended March 31,

 

2003

 

2002

 

 

 


 


 

Net revenues

 

$

4,443,568

 

$

2,506,288

 

Cost of sales

 

 

2,011,129

 

 

1,249,445

 

 

 



 



 

Gross profit

 

 

2,432,439

 

 

1,256,843

 

 

 



 



 

Operating expenses:

 

 

 

 

 

 

 

Selling

 

 

1,285,228

 

 

794,093

 

General and administrative

 

 

1,164,445

 

 

936,933

 

Research and development

 

 

346,726

 

 

358,495

 

 

 



 



 

Total operating expenses

 

 

2,796,399

 

 

2,089,521

 

 

 



 



 

Loss from operations

 

 

(363,960

)

 

(832,678

)

 

 



 



 

Other income:

 

 

 

 

 

 

 

Interest income

 

 

51,207

 

 

166,806

 

Other income (expense), net

 

 

38,811

 

 

(15,078

)

 

 



 



 

Total other income, net

 

 

90,018

 

 

151,728

 

 

 



 



 

Loss from continuing operations before income taxes

 

 

(273,942

)

 

(680,950

)

Provision for income taxes

 

 

13,418

 

 

33,322

 

 

 



 



 

Net loss

 

$

(287,360

)

$

(714,272

)

 

 



 



 

Basic and diluted loss per common share

 

$

(.01

)

$

(.02

)

 

 



 



 

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:

 

 

 

 

 

 

 

Basic and diluted

 

 

27,519,079

 

 

28,635,652

 

 

 



 



 


The accompanying Notes to Consolidated Financial Statements are an integral part of these statements.


3


Table of Contents

IVAX DIAGNOSTICS AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

 

Three Months Ended March 31,

 

2003

 

2002

 

 

 


 


 

Cash flows from operating activities:

 

 

 

 

 

 

 

Net loss

 

$

(287,360

)

$

(714,272

)

Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

 

287,024

 

 

186,374

 

Provision for losses on accounts receivable

 

 

71,985

 

 

29,691

 

Stock option compensation expense

 

 

148,650

 

 

148,650

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable

 

 

(545,655

)

 

(359,986

)

Inventories

 

 

305,835

 

 

158,887

 

Other current assets

 

 

(41,210

)

 

70,338

 

Other assets

 

 

158

 

 

1,051

 

Accounts payable and accrued expenses

 

 

652,775

 

 

(68,338

)

Other long-term liabilities

 

 

16,390

 

 

7,749

 

 

 



 



 

Net cash flows provided by (used in) operating activities

 

 

608,592

 

 

(539,856

)

 

 



 



 

Cash flows from investing activities:

 

 

 

 

 

 

 

Capital expenditures

 

 

(34,530

)

 

(23,389

)

Acquisitions of marketable securities

 

 

 

 

(2,050,000

)

Acquisitions of equipment on lease

 

 

(157,488

)

 

(179,006

)

 

 



 



 

Net cash flows used in investing activities

 

 

(192,018

)

 

(2,252,395

)

 

 



 



 

Cash flows from financing activities:

 

 

 

 

 

 

 

Change in balance due to IVAX Corporation

 

 

 

 

82,000

 

 

 



 



 

Net cash flows provided by financing activities

 

 

 

 

82,000

 

 

 



 



 

Effect of exchange rate changes on cash and cash equivalents

 

 

30,930

 

 

(32,959

)

 

 



 



 

Net increase (decrease) in cash and cash equivalents

 

 

447,504

 

 

(2,743,210

)

Cash and cash equivalents at the beginning of the year

 

 

15,941,663

 

 

23,282,155

 

 

 



 



 

Cash and cash equivalents at the end of the period

 

$

16,389,167

 

$

20,538,945

 

 

 



 



 

Supplemental disclosures:

 

 

 

 

 

 

 

Interest paid

 

$

 

$

 

 

 



 



 

Income tax payments (refunds)

 

$

 

$

 

 

 



 



 


The accompanying Notes to Consolidated Financial Statements are an integral part of these statements.